Chardan Capital Reiterates Buy Rating for REGENXBIO (NASDAQ:RGNX)
REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $52.00 price target on the biotechnology company’s stock. A number of other research analysts have also recently issued reports on the stock. Raymond James […]
REGENXBIO (NASDAQ:RGNX – Get Free Report)‘s stock had its “buy” rating reaffirmed by equities researchers at Chardan Capital in a note issued to investors on Friday,Benzinga reports. They presently have a $52.00 price target on the biotechnology company’s stock. A number of other research analysts have also recently issued reports on the stock. Raymond James […]
